Close
28/05/2015
Synchrotron light applications for the pharmaceutical industry
More than forty people from the pharmaceutical sector attended the workshop organised by the ALBA Synchrotron on May 7.

Researchers from the MSPD, CLAESS, XALOC, NCD and MISTRAL ALBA beam lines have shown the available state-of-the-art techniques and the advantages that they offer in this field: fast data acquisition and shorter experiments, cost savings and, in the case of X-ray microscopy, suppression of ethical conflicts because this technique can be a previous step before clinical essays with animals and persons.

The companies Enantia and Almirall, which have already collaborated with the ALBA Synchrotron, have commented their own experiences at the facility. Enantia, specialised in research solutions for other companies, has detailed different examples. For Almirall, the analysis of polymorphic compounds – performed at ALBA – has increased its quality control, verifying and quantifying purity grades.

News based on the press release issued by the ALBA synchrotron.

Image: ALBA synchrotron. Structure of a herpesvirus nuclease-antiviral complex. Data collected at the Xaloc beam line (Bongarzone, S., Nadal, M. & Coll, M., IBMB)

More news

13/04/2023 Panattoni acquires 60,000 sqm land plot to build a data center 16/09/2021 Battery technology in the Barcelona Synchrotron Park environment 06/09/2021 Advances in the creation of a state-of-the-art microscopy platform at the Alba Synchrotron 22/07/2021 IBM, the big blue of technology at the Barcelona Synchrotron Park 02/07/2021 SENER, cutting-edge engineering and technology in the Barcelona Synchrotron Park 11/06/2021 Parc de l'Alba: first injection of landfill gas into the distribution network
1 2 3 4 5 6